Complement inhibitors in clinical trials for glomerular diseases

95Citations
Citations of this article
129Readers
Mendeley users who have this article in their library.

Abstract

Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).

Cite

CITATION STYLE

APA

Zipfel, P. F., Wiech, T., Rudnick, R., Afonso, S., Person, F., & Skerka, C. (2019, September 1). Complement inhibitors in clinical trials for glomerular diseases. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2019.02166

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free